Global Business Reports


Catherine Howe, Neha Premjee, Emma Johannes

United States Biopharmaceuticals 2018 Pre-Release

March 15, 2018

A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is recognized as the most prominent proponent of medical innovation around the world. As the industry moves from treatments towards cures and pipelines are developed around the notion of precision medicine, more and more life-changing therapies are entering the market. With an increasing amount of innovation stemming from small biotechnology companies and university spin-offs, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange. GBR’s 2018 U.S. Biopharmaceuticals Pre-release shines a spotlight on the Boston/Cambridge area and San Francisco Bay Area as top destinations for investment and biopharmaceutical activity.


Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.


Motion Mertics explains how the latest technologies are being deployed in African mines.